Seven Fleet Capital Management LP Acquires New Holdings in Definium Therapeutics, Inc. $DFTX

Key Points

• Seven Fleet Capital Management acquired 148,647 shares of Definium Therapeutics, worth approximately $6.99 million, making up 1.2% of its portfolio and representing 0.11% of the company. Institutional investors collectively own 27.91% of the stock.
• Definium reported quarterly adjusted losses of $1.44 per share, missing analyst expectations by $0.89. Analysts nonetheless maintain a consensus “Buy” rating with an average price target of $63, compared with the stock’s reported price of $38.09.
• Company insiders sold 67,119 shares worth approximately $2.89 million during the last quarter, while insiders retain a 2.40% ownership stake.

Seven Fleet Capital Management LP bought a new stake in shares of Definium Therapeutics, Inc. (NASDAQ:DFTX - Free Report) in the second quarter, according to its most recent Form 13F filing with the SEC. The fund bought 148,647 shares of the company's stock, valued at approximately $6,992,000. Definium Therapeutics accounts for 1.2% of Seven Fleet Capital Management LP's investment portfolio, making the stock its 20th largest position. Seven Fleet Capital Management LP owned 0.11% of Definium Therapeutics at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Russell Investments Group Ltd. increased its stake in shares of Definium Therapeutics by 110.4% in the second quarter. Russell Investments Group Ltd. now owns 3,817 shares of the company's stock valued at $25,000 after purchasing an additional 2,003 shares during the period. Nykredit A S bought a new stake in shares of Definium Therapeutics during the second quarter valued at approximately $45,000. BNP Paribas Financial Markets boosted its position in shares of Definium Therapeutics by 56.0% during the second quarter. BNP Paribas Financial Markets now owns 8,417 shares of the company's stock worth $55,000 after buying an additional 3,020 shares during the period. Caxton Associates LLP acquired a new position in shares of Definium Therapeutics during the third quarter worth approximately $126,000. Finally, ExodusPoint Capital Management LP bought a new position in Definium Therapeutics in the 4th quarter worth approximately $254,000. Institutional investors own 27.91% of the company's stock.

Definium Therapeutics Stock Up 0.2%

NASDAQ:DFTX opened at $38.09 on Friday. Definium Therapeutics, Inc. has a 1-year low of $8.77 and a 1-year high of $49.70. The firm has a market capitalization of $5.12 billion, a price-to-earnings ratio of -11.10 and a beta of 2.23. The company has a current ratio of 6.95, a quick ratio of 6.95 and a debt-to-equity ratio of 0.04. The business's fifty day moving average price is $43.70 and its 200 day moving average price is $29.49.

Definium Therapeutics (NASDAQ:DFTX - Get Free Report) last posted its quarterly earnings results on Thursday, August 6th. The company reported ($1.44) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.55) by ($0.89). On average, sell-side analysts forecast that Definium Therapeutics, Inc. will post -3.02 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of analysts have recently weighed in on the stock. Piper Sandler reaffirmed an "overweight" rating and issued a $75.00 price target (up from $73.00) on shares of Definium Therapeutics in a research note on Friday, August 7th. Canaccord Genuity Group set a $64.00 price objective on shares of Definium Therapeutics and gave the stock a "buy" rating in a research note on Thursday, August 13th. Wells Fargo & Company boosted their target price on shares of Definium Therapeutics from $68.00 to $72.00 and gave the stock an "overweight" rating in a report on Thursday, August 13th. Citigroup reissued a "buy" rating on shares of Definium Therapeutics in a research note on Monday, June 22nd. Finally, Weiss Ratings restated a "sell (d-)" rating on shares of Definium Therapeutics in a research report on Friday, July 17th. Two research analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company currently has an average rating of "Buy" and a consensus price target of $63.00.

Insider Activity at Definium Therapeutics

In related news, CFO Brandi Roberts sold 3,013 shares of the stock in a transaction on Thursday, June 25th. The stock was sold at an average price of $45.03, for a total transaction of $135,675.39. Following the completion of the sale, the chief financial officer directly owned 209,487 shares in the company, valued at approximately $9,433,199.61. This trade represents a 1.42% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Matthew Wiley sold 2,867 shares of Definium Therapeutics stock in a transaction on Thursday, June 25th. The shares were sold at an average price of $45.03, for a total value of $129,101.01. Following the sale, the insider directly owned 174,633 shares of the company's stock, valued at approximately $7,863,723.99. The trade was a 1.62% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders have sold 67,119 shares of company stock valued at $2,887,496. Insiders own 2.40% of the company's stock.

About Definium Therapeutics

Definium Therapeutics, Inc, a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company's lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of core symptoms of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc and changed its name to Definium Therapeutics, Inc in January 2026.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source